American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.

Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Monday, April 4, 2022 Late Breaking Clinical Trials

More News from ACC on Patient Care

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.